A witness explained the difficulties she experienced in accessing treatment for Hepatitis C. Read more about A witness explained the difficulties she experienced in accessing treatment for Hepatitis C.
Jean Smith explained the difficulties she encountered in accessing treatment for Hepatitis C. Read more about Jean Smith explained the difficulties she encountered in accessing treatment for Hepatitis C.
The psychosocial expert group reported to the Inquiry that a breakdown in trust between a patient and healthcare provider has been shown to have deleterious effects on quality of care across all serious health problems. Having to continue attending for healthcare in the treatment setting where the infected blood had been given was clearly "a major source of distress for many individuals." Read more about The psychosocial expert group reported to the Inquiry that a breakdown in trust between a patient and healthcare provider has been shown to have deleterious effects on quality of care across all serious health problems. Having to continue attending for healthcare in the treatment setting where the infected blood had been given was clearly "a major source of distress for many individuals."
World Health Organisation Fact Sheet on Palliative Care defined palliative care as an approach that improves the quality of life of patients facing problems associated with life threatening illness. Read more about World Health Organisation Fact Sheet on Palliative Care defined palliative care as an approach that improves the quality of life of patients facing problems associated with life threatening illness.
Clinical guidelines on the management of hepatitis C were published. Read more about Clinical guidelines on the management of hepatitis C were published.
An article on the variation in Hepatitis C services in the UK was published, which found that the majority of patients were not receiving antiviral treatment, in contrast with practice in Europe. Read more about An article on the variation in Hepatitis C services in the UK was published, which found that the majority of patients were not receiving antiviral treatment, in contrast with practice in Europe.
Daniel Eve explained NHS England funded off-label usage of recombinant blood products for post-pubertal children with Von Willebrand Disease. NHS England is in the early stages of considering the possibility of off-label usage for patients under 12. Read more about Daniel Eve explained NHS England funded off-label usage of recombinant blood products for post-pubertal children with Von Willebrand Disease. NHS England is in the early stages of considering the possibility of off-label usage for patients under 12.
In Northern Ireland, access to recombinant blood products for children with von Willebrand disorder is available in exceptional cases through the Individual Funding Request ("IFR") route, however to date no IFR has been made. Read more about In Northern Ireland, access to recombinant blood products for children with von Willebrand disorder is available in exceptional cases through the Individual Funding Request ("IFR") route, however to date no IFR has been made.
Caroline Lamb explained children in Scotland can receive recombinant von Willebrand Factor if appropriate. Read more about Caroline Lamb explained children in Scotland can receive recombinant von Willebrand Factor if appropriate.
Judith Paget explained children in Wales can receive recombinant von Willebrand Factor off-label for on-demand treatment of non-surgical and surgical bleeding episodes. Read more about Judith Paget explained children in Wales can receive recombinant von Willebrand Factor off-label for on-demand treatment of non-surgical and surgical bleeding episodes.